BOYANG WANG LAUNCHES $40 MILLION LONGEVITY FUND TO ADVANCE RADICAL LIFE EXTENSION

With $40 million, 15 companies, a podcast, global outreach, and personal skin in the game, Immortal Dragons is no longer just a fund. It’s a signal — a signal that the race to overcome aging has truly begun, and that its first great champions are already in the arena.

In a world where the inevitability of aging has long been accepted as fact, a bold new force is rising to challenge the status quo. Headquartered in Singapore but thinking globally, Immortal Dragons is no ordinary investment fund. It is a declaration of war — against biological decline, premature death, and the silent assumption that aging must remain a mystery we simply endure.

On July 16, 2025, Immortal Dragons officially unveiled its $40 million longevity fund, marking a pivotal moment for a movement gaining unstoppable momentum. But this isn’t just another venture capital announcement. This is a mission in motion — one rooted in purpose, unafraid of risk, and unapologetically focused on the one goal that unites all of us: more life, better lived.

Behind this ambitious initiative is Boyang Wang, a founder whose vision extends far beyond financial gain. His goal is nothing less than to fund the radical breakthroughs that could redefine what it means to be human.

“Aging and death are technical challenges,” Wang said. “We’re not here just to invest — we’re here to solve.”

And solve they might.

Rethinking Aging as a Technical Problem

Immortal Dragons operates under a philosophy that’s as controversial as it is compelling: aging is not inevitable. Instead, it’s a biological process — one with identifiable mechanisms, modifiable pathways, and ultimately, solvable problems.

This perspective turns conventional thinking on its head. Where others see decay, Immortal Dragons sees data. Where others see death, they see delay — and maybe, eventually, escape.

The fund is taking aim at some of the most promising yet underfunded frontiers in science: gene therapy to slow aging at its source, bioprinted tissues to replace failing organs, cryopreservation to bridge the gap between today's science and tomorrow’s cures, and even regulatory sandboxes to fast-track clinical research.

These aren’t incremental improvements. They’re moonshots — the kinds of ideas that make cautious investors squirm, but that could alter human history if they work.

Moonshot Meets Method: A New Model for Longevity Capital

What sets Immortal Dragons apart isn’t just what they’re funding — it’s how they’re doing it. With a single-LP structure, they’re not beholden to dozens of traditional backers or quarterly ROI benchmarks. Instead, they’re deploying their own capital with the agility and clarity that only purpose-driven money can offer.

That independence has already enabled them to support over 15 startups across the global longevity ecosystem. Some are pursuing technologies straight out of science fiction. Others are building the infrastructure — from special economic zones to trial accelerators — that make those scientific dreams operational.

Wang is as much a futurist as he is an investor, and his conviction runs deeper than portfolio reports. He’s one of the first 300 people globally to undergo follistatin gene therapy, a cutting-edge treatment developed by biotech startup Minicircle.

“The therapy is a personal experiment, yes,” Wang admits, “but it reflects our risk appetite — and our belief in what’s coming.”

This approach — part venture capital, part scientific pilgrimage — signals a new kind of investor. One who isn’t waiting for the future to arrive. He’s participating in it.

Beyond Capital: Building the Longevity Culture

But funding alone isn’t enough. The team at Immortal Dragons knows that for longevity to truly go mainstream, it must be supported by culture, education, and global collaboration.

That’s why the fund has made advocacy and outreach a cornerstone of its mission. From translating longevity books and scientific lectures into Chinese, to hosting the leading Chinese-language longevity podcast, to sponsoring major conferences like ARDD 2025 and supporting communities like Vitalist Bay in Berkeley, Immortal Dragons is building not just a portfolio — but a movement.

This East-meets-West strategy has made them a unique bridge in the global longevity landscape. As aging research accelerates in the West, Immortal Dragons is actively laying the groundwork to amplify these advances throughout Asia, where interest is surging but institutional support remains scattered.

The fund’s advocacy efforts have earned praise from top researchers around the world.

Professor Peter Lidsky, of City University of Hong Kong, noted the fund’s impact firsthand after collaborating with them on translated academic content.

“These are young, brave, and energetic people committed to resolving the main challenge humanity faces: aging,” Lidsky said. “Their support helped bring my work to new audiences, and I believe our partnership is just beginning.”

Even legendary longevity pioneer Aubrey de Grey, founder of the LEV Foundation, has taken notice.

“I’ve been frustrated by the lack of longevity activism in China for years,” de Grey remarked. “Now, that’s changing — thanks to Immortal Dragons. They’re not only translating our work but also investing in the companies that are turning theory into therapy.”

As the longevity field matures, more investors will enter. Some will chase trends. Others will follow the money. But a few — like Immortal Dragons — will lead with vision.

The Audacity of Immortality

There’s something undeniably audacious about naming your fund Immortal Dragons. It speaks to ambition, legacy, and fire — the fire to resist entropy, to reject complacency, and to burn brighter than biology says you should.

But behind the name lies a thoughtful, strategic approach to what is perhaps the most profound human challenge: how to make life not just longer, but better.

For Wang and his team, longevity isn’t about vanity. It’s not about chasing eternal youth or uploading minds to machines. It’s about giving people more healthy years to love, build, explore, and contribute. It’s about ending the grief of watching parents or partners fade before their time. And yes, it’s about the possibility — however distant — that death might one day be optional.

A Movement That Won’t Wait

The timing couldn’t be more urgent. Around the world, populations are aging. Healthcare systems are strained. Millions are suffering and dying from diseases that might, in a decade or two, be preventable — if the research is funded now.

And yet, longevity remains drastically undercapitalized compared to its potential impact. Many promising studies never make it past the lab bench. Clinical trials stall. Regulatory hurdles pile up. All because the money — and the political will — hasn’t caught up with the science.

Immortal Dragons is trying to change that.

“We need more than hope,” Wang says. “We need a flywheel — where investment leads to breakthroughs, which lead to profits, which fund the next wave of discoveries.”

This is the long game. And it’s not for the faint of heart. But if Immortal Dragons has proven anything, it’s that bold action, backed by conviction, can shift what’s possible.

Conclusion: Lighting the Way Forward

As the longevity field matures, more investors will enter. Some will chase trends. Others will follow the money. But a few — like Immortal Dragons — will lead with vision. In a world filled with funds promising 10x returns, this one is offering something different: a shot at 10x more life. Not everyone will believe it’s possible. Not yet. But belief is only the beginning. What matters is what comes next: action, experimentation, failure, learning — and progress.

And progress is exactly what this field needs. Not in 20 years. Not when it’s safer. Now.

With $40 million, 15 companies, a podcast, global outreach, and personal skin in the game, Immortal Dragons is no longer just a fund. It’s a signal — a signal that the race to overcome aging has truly begun, and that its first great champions are already in the arena.

The fire has been lit. The question is: who will follow?

---

Note: The information provided in this article is intended for informational purposes only and does not constitute medical advice. Always consult a healthcare provider before starting any new supplement or health regimen.

---